Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash, plus potential near‑term milestone payments and royalties. The deal brings SomaLogic’s SomaScan/aptamer proteomics technology and a CLIA/CAP‑certified lab in Boulder into Illumina’s portfolio and supports its Protein Prep sequencing‑based readout ambitions. Illumina said it has no immediate plans to change operations in Boulder and will leverage its global manufacturing and commercial footprint to scale the technology. The acquisition follows prior co‑development work between Illumina and SomaLogic to create a sequencing‑based protein readout. For genomics and proteomics markets, the purchase represents a move by Illumina to bridge sequencing and high‑throughput protein measurement, signaling increased competition in clinical proteomics and a push to integrate multi‑omic diagnostic capabilities under large platform providers.